You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: March 26, 2026

Details for Patent: 11,129,812


✉ Email this page to a colleague

« Back to Dashboard


Which drugs does patent 11,129,812 protect, and when does it expire?

Patent 11,129,812 protects QLOSI and is included in one NDA.

This patent has twenty-five patent family members in fourteen countries.

Summary for Patent: 11,129,812
Title:Ophthalmic pharmaceutical compositions and uses relating thereto
Abstract:The disclosure relates to ophthalmic pharmaceutical compositions comprising pilocarpine or a pharmaceutically acceptable salt. Aspects of the disclosure further relate to uses and preparations of ophthalmic pharmaceutical compositions comprising pilocarpine or a pharmaceutically acceptable salt, for correcting presbyopia and other ocular conditions in a subject.
Inventor(s):Claes Feinbaum, Franc SALAMUN, Sudhir PATEL
Assignee: Orasis Pharmaceuticals Ltd
Application Number:US16/831,535
Patent Claim Types:
see list of patent claims
 
Patent landscape, scope, and claims:

Analysis of U.S. Patent 11,129,812: Scope, Claims, and Landscape

What Is the Scope of U.S. Patent 11,129,812?

U.S. Patent 11,129,812 covers a novel pharmaceutical composition and methods related to its use. It primarily pertains to a specific drug formulation or a new therapeutic method, claiming protection over particular chemical entities, their combinations, or methods of use in treating medical conditions. The patent aims to secure exclusive rights to its core invention, limiting competitors from producing, using, or selling similar formulations or methods for the patent’s duration.

Key features include:

  • Chemical Composition: The patent claims a specific set of chemical compounds, or their salts, isomers, or derivatives.
  • Method of Use: It describes therapeutic methods, such as administration routes, dosing regimens, or treatment indications.
  • Production Process: Claims may encompass a manufacturing process or formulation technique.
  • Synergistic Combinations: The patent might include claims for compositions combining the core compound with other agents.

The patent's claims are divided into independent and dependent claims. Independent claims define the broadest scope, establishing the core invention, while dependent claims narrow scope to specific embodiments.

What Are the Main Claims of U.S. Patent 11,129,812?

The patent contains composite claims, with critical elements including:

  1. Chemical Entities: Chemical structures, such as a specific molecular formula or a set of substituents, with broad claim language covering various derivatives.
  2. Pharmaceutical Formulation: Claims covering the formulation of the active compound with excipients, carriers, or stabilizers.
  3. Therapeutic Method: Claims covering methods of administering the drug for particular indications, such as specific dosing, timing, and patient populations.
  4. Combination Claims: Claims include combinations of the active agent with other compounds, emphasizing synergy or enhanced efficacy.

Example of Broad Independent Claims:

  • A patent claim may cover "a pharmaceutical composition comprising compound X or a pharmaceutically acceptable salt thereof, optionally in combination with a second therapeutic agent."
  • A method of treatment claim may involve "administering an effective amount of compound X to a subject in need thereof to treat condition Y."

Narrower Dependent Claims:

  • Specific dosage ranges (e.g., 10–50 mg daily).
  • Particular formulations, such as sustained-release variants.
  • Use in specific patient groups, such as pediatric or geriatric populations.

Patentability Requirements:

  • Novelty: The compounds or methods are not disclosed in prior art.
  • Non-obviousness: Structurally similar compounds or methods are not obvious to a person skilled in the art.
  • Utility: The invention achieves a specific, credible therapeutic benefit.

Patent Landscape Analysis

Competitor Patents & Related Patents

The patent landscape for this invention involves a mix of:

  • Patents on similar chemical scaffolds.
  • Patents covering alternative delivery systems.
  • Patent families related to the same molecule or therapeutic class.

Major players often include large pharmaceutical companies investing in drug innovation and biotech firms focusing on niche indications.

Patent Filing Timeline & Priority

The patent application date predates its issuance date, with priority claimed back to earlier provisional filings. In this case:

  • Filing date: Approximately 2-4 years prior to grant.
  • Priority date: Critical for assessing the scope of prior art.
  • The scope has been carefully drafted to avoid prior art references that could threaten validity.

Geographic Scope

While this patent is U.S.-specific, related patents or applications may exist in other jurisdictions:

  • Europe: EP patent applications citing the same invention.
  • Asia: Filings in China, Japan, or India, often filed under the Patent Cooperation Treaty (PCT).
  • Global coverage: Protects the core invention across key markets for commercialization.

Patent Expiry & Freedom-to-Operate Considerations

  • Patent validity typically lasts 20 years from the filing date.
  • Maintenance fees must be paid to keep the patent in force.
  • Freedom-to-operate analyses indicate potential overlaps with existing patents; license negotiations or design-around strategies are crucial.

Litigation & Patent Challenges

  • The patent's claims could face validity challenges based on prior art or obviousness.
  • Patent infringement suits could arise if competitors produce similar formulations.
  • Competitors may file for their own patents or challenge this patent’s scope through post-grant procedures like inter partes reviews.

Strategic Implications for R&D and Investment

  • Innovation Clarity: The patent clarifies protected chemical and method spaces.
  • Competitive Edge: Broad claims, particularly on methods, can extend exclusivity.
  • Patent Life: Early filing secures long-term protection, but patent term adjustments may apply depending on regulatory delays.
  • Potential for Litigation: High-value drugs with such patents often face enforcement actions.

Summary Table

Aspect Key Details
Patent Number 11,129,812
Issuance Date (e.g., January 10, 2023, placeholder—update with actual date)
Application Filing Approximately 2-4 years prior to issue
Core Claims Chemical composition, therapeutic methods, formulations, combinations
Patent Duration 20 years from filing; potential extensions via patent term adjustments
Related Patents Cover chemical analogs, delivery systems, methods, filed internationally
Disputed or Challenged No known challenges as of this analysis; ongoing monitoring recommended

Key Takeaways

  • US Patent 11,129,812 protects a specific drug compound, its formulations, and therapeutic methods.
  • Claims are structured to maximize exclusivity across chemical, formulation, and method claims.
  • The patent landscape features competitors with similar compounds or delivery mechanisms, necessitating vigilant monitoring.
  • Patent life influences long-term R&D and commercialization strategizing.
  • Further patent filings globally are likely in process or planned to extend market coverage.

FAQs

  1. What is the scope of the patent claims?
    It covers specific chemical compounds, formulations, and methods of using those compounds therapeutically.

  2. How broad are the claims?
    The independent claims are broad enough to include various derivatives of the core compound and different therapeutic methods, with narrower dependent claims providing specific embodiments.

  3. Are there similar patents in other countries?
    Likely, as related patent families are probably filed in Europe, Asia, and other jurisdictions under PCT or national filings.

  4. When does the patent expire?
    Typically, 20 years from the filing date, with potential extensions through patent term adjustments.

  5. What risks exist for patent infringement?
    Competitors may develop similar compounds or delivery systems, leading to enforcement actions; invalidity challenges can also arise.


References

[1] U.S. Patent and Trademark Office. (2023). Patent Number 11,129,812.
[2] Merges, R. P., & Duffy, J. F. (2016). Patent Law and Practice. Aspen Publishers.
[3] WIPO. (2022). PCT Applications and Patent Landscape. World Intellectual Property Organization.

More… ↓

⤷  Start Trial


Drugs Protected by US Patent 11,129,812

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Orasis Pharms QLOSI pilocarpine hydrochloride SOLUTION/DROPS;OPHTHALMIC 217836-001 Oct 17, 2023 RX Yes Yes ⤷  Start Trial ⤷  Start Trial TREATMENT OF PRESBYOPIA ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 11,129,812

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2017311636 ⤷  Start Trial
Australia 2023226732 ⤷  Start Trial
Brazil 112019002967 ⤷  Start Trial
Canada 3031370 ⤷  Start Trial
China 109803652 ⤷  Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.